Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1150 mg double-blinded secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
2150 mg open-label secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
3300 mg double-blinded secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
4After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
(D09967)		[2] Secukinumab,
Ustekinumab		[2] Ustekinumab ,
Secukinumab (D09967) 💬 		[4] IL12A,
IL12B,
IL17A,
IL23A 💬 		[29] African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬[1] 37 💬
5Other: Secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[2] 107, 271 💬
6SECUKINUMAB
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
7Secukinumab (150 mg)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
8Secukinumab (75 mg)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
9Secukinumab (AIN457)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 46 💬
10Secukinumab (AIN457) 150 mg s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
11Secukinumab 150 mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
12Secukinumab 150 mg (2 injections per dose
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 269 💬
13Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
14Secukinumab 150 mg/1 ml Solution for injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[2] 37, 271 💬
15Secukinumab 150 mg/ml
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
16Secukinumab 150 milligram [Cosentyx]
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
17Secukinumab 150mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 37 💬
18Secukinumab 150mg s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
19Secukinumab 300 mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
20Secukinumab 300 mg, s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
21Secukinumab 300mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 37 💬
22Secukinumab 300mg s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
23Secukinumab 75 mg/0.5 ml Solution for injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
24Secukinumab Injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬 [1] IL17A 💬 [6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 160 💬
25Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age
(D09967)		[2] Dupilumab,
Secukinumab		[2] Secukinumab (D09967),
Dupilumab 💬 		[2] IL17A,
IL4R 💬 		[11] Alcoholic liver disease, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 160 💬